The novel HLA-DPB1*04:02:01:44 allele identified in a volunteer bone marrow donor.

Nucleotide substitution in the intron 2 of HLA-DPB1*04:02:01:01 results in a novel allele, HLA-DPB1*04:02:01:44.

The novel HLA-B*35:01:77 allele identified in a Russian volunteer bone marrow donor.

Nucleotide substitutions in the 5'UTR and exon 2 of HLA-B*35:01:01:05 result in a novel allele, HLA-B*35:01:77.

Clonal structure and the specificity of vaccine-induced T cell response to SARS-CoV-2 Spike protein.

Adenovirus vaccines, particularly the COVID-19 Ad5-nCoV adenovirus vaccine, have emerged as promising tools in the fight against infectious diseases. In this study, we investigated the structure of the T cell response to the Spike protein of the SARS-CoV-2 virus used in the COVID-19 Ad5-nCoV adenoviral vaccine in a phase 3 clinical trial (NCT04540419). In 69 participants, we collected peripheral blood samples at four time points after vaccination or placebo injection. Sequencing of T cell receptor repertoires from Spike-stimulated T cell cultures at day 14 from 17 vaccinated revealed a more diverse CD4+ T cell repertoire compared to CD8+. Nevertheless, CD8+ clonotypes accounted for more than half of the Spike-specific repertoire. Our longitudinal analysis showed a peak T cell response at day 14, followed by a decline until month 6. Remarkably, multiple T cell clonotypes persisted for at least 6 months after vaccination, as demonstrated by ex vivo stimulation. Examination of CDR3 regions revealed homologous sequences in both CD4+ and CD8+ clonotypes, with major CD8+ clonotypes sharing high similarity with annotated sequences specific for the NYNYLYRLF peptide, suggesting potential immunodominance. In conclusion, our study demonstrates the immunogenicity of the Ad5-nCoV adenoviral vaccine and highlights its ability to induce robust and durable T cell responses. These findings provide valuable insight into the efficacy of the vaccine against COVID-19 and provide critical information for ongoing efforts to control infectious diseases.

HLA-A*24:521 and HLA-B*13:152 identified by next-generation sequencing in Russian bone marrow donors.

Two novel alleles, HLA-A*24:521 and HLA-B*13:152, are characterized.

Two novel HLA alleles identified in Russian bone marrow donors: HLA-A*02:957 and -C*12:03:67.

Characterization of two novel HLA class I alleles, A*02:957 and C*12:03:67.

The novel HLA-A*26:01:64 allele, identified by next-generation sequencing in a bone marrow donor of Bashkir origin.

HLA-A*26:01:64 has one nucleotide difference from HLA-A*26:01: 01:01 at gDNA position 989 (G→A).

Immunogenetic Factors of Predisposition to Blood Malignancies in Russian Population.

HLA class II loci (DRB1, DQB1) have been investigated in patients with different blood tumors: acute myelogenous leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia and Hodgkin's disease. The purpose was to determine the general (common) markers of predisposition (or resistance) in HLA class II loci to malignant changing of hemopoiesis in Russian population, and to verify the individual associations between HLA and disease for each examined neoplasm. It has been found that: 1). DRB1*11 is general (common) factor of predisposition to all investigated blood neoplasms. 2). In HLA class II loci there are factors of predisposition to one-third of neoplasms such as DRB1*12 DQB1*0503, 0301 for acute lymphoblastic leukemia, DRB1*14, DQB1*0503, 0601 for chronic myelogenous leukemia, DQB1*0503 and 0301 for Hodgkin's disease. Our findings support the hypothesis that there are structures associated with HLA system, which predispose to malignant change of hemopoiesis in general, and other HLA structures, which "turn" the change into concrete nosological form. Both factors are linked with HLA class II loci.